JP2022548778A5 - - Google Patents
Info
- Publication number
- JP2022548778A5 JP2022548778A5 JP2022518209A JP2022518209A JP2022548778A5 JP 2022548778 A5 JP2022548778 A5 JP 2022548778A5 JP 2022518209 A JP2022518209 A JP 2022518209A JP 2022518209 A JP2022518209 A JP 2022518209A JP 2022548778 A5 JP2022548778 A5 JP 2022548778A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962904340P | 2019-09-23 | 2019-09-23 | |
| US62/904,340 | 2019-09-23 | ||
| PCT/US2020/052227 WO2021061778A1 (en) | 2019-09-23 | 2020-09-23 | Disrupting tumor tissues by targeting fibroblast activation protein (fap) |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022548778A JP2022548778A (ja) | 2022-11-21 |
| JP2022548778A5 true JP2022548778A5 (https=) | 2023-09-06 |
| JPWO2021061778A5 JPWO2021061778A5 (https=) | 2023-09-06 |
| JP7621344B2 JP7621344B2 (ja) | 2025-01-24 |
Family
ID=74881688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518209A Active JP7621344B2 (ja) | 2019-09-23 | 2020-09-23 | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とすることによる腫瘍組織の破壊の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12116418B2 (https=) |
| EP (1) | EP4034554A4 (https=) |
| JP (1) | JP7621344B2 (https=) |
| KR (1) | KR20220066312A (https=) |
| CN (1) | CN114746438A (https=) |
| AU (1) | AU2020353000A1 (https=) |
| BR (1) | BR112022005423A2 (https=) |
| CA (1) | CA3151550A1 (https=) |
| IL (1) | IL291342A (https=) |
| MX (1) | MX2022003466A (https=) |
| WO (1) | WO2021061778A1 (https=) |
| ZA (1) | ZA202203511B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| WO2021061708A1 (en) | 2019-09-23 | 2021-04-01 | The Trustees Of The Univeristy Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2022033483A1 (zh) * | 2020-08-10 | 2022-02-17 | 佧珐药业有限公司 | 多功能的免疫效应细胞及其应用 |
| JP2024519041A (ja) * | 2021-05-21 | 2024-05-08 | セレクティス ソシエテ アノニム | 固形腫瘍における癌関連線維芽細胞を調節することによるｔ細胞媒介性免疫療法の効力の増強 |
| AU2023290273A1 (en) * | 2022-06-14 | 2024-12-12 | Purdue Research Foundation | Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025006799A1 (en) | 2023-06-27 | 2025-01-02 | Capstan Therapeutics, Inc. | Extracorporeal and ex vivo engineering of select cell populations from peripheral blood |
| CN116908455A (zh) * | 2023-07-25 | 2023-10-20 | 广西师范大学 | 一种检测癌胚抗原的光电化学免疫传感器的制备方法及其应用 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| WO2025096842A2 (en) * | 2023-11-03 | 2025-05-08 | Amgen Inc. | Fibroblast targeting molecules |
| WO2025129201A1 (en) | 2023-12-15 | 2025-06-19 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN119060202A (zh) * | 2024-08-12 | 2024-12-03 | 华中科技大学同济医学院附属协和医院 | 一种靶向fap的嵌合抗原受体调节性t细胞、其制备方法与应用 |
| CN119074926B (zh) * | 2024-08-29 | 2025-11-25 | 中国医学科学院阜外医院深圳医院(深圳市孙逸仙心血管医院) | 一种靶向fap的car-t细胞在制备治疗心肌炎慢性期心脏纤维化的药物中的应用 |
| CN119285786B (zh) * | 2024-10-15 | 2025-10-03 | 普飞(郑州高新技术产业开发区)生物科技有限公司 | 一种抗fap的纳米抗体及其应用 |
| CN119591719B (zh) * | 2024-11-25 | 2025-10-21 | 江苏集萃崛创生物科技研究所有限公司 | 靶向fap的纳米抗体、car-t细胞及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| ATE446366T1 (de) * | 2000-06-22 | 2009-11-15 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
| CA2533593A1 (en) | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc. | Altered antibodies having improved antigen-binding affinity |
| EP2628753A1 (en) | 2008-01-24 | 2013-08-21 | Novo Nordisk A/S | Humanized anti-human NKG2A monoclonal antibody |
| EP2483316A1 (en) | 2009-10-02 | 2012-08-08 | Ludwig Institute for Cancer Research Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| HUE036077T2 (hu) | 2010-08-13 | 2018-06-28 | Roche Glycart Ag | Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások |
| WO2013040557A2 (en) * | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| US20160136272A1 (en) | 2013-05-14 | 2016-05-19 | Innate Pharma | Methods for restoring corticosteroid sensitivity |
| AU2014312215B2 (en) * | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| CA2921639A1 (en) | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| US20170081411A1 (en) | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| TWI736575B (zh) | 2016-01-22 | 2021-08-21 | 美商默沙東藥廠 | 抗凝固因子ｘｉ抗體 |
| MY209117A (en) | 2016-04-15 | 2025-06-23 | Novartis Ag | Compositions and methods for selective protein expression |
| JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| CN107663240B (zh) | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| WO2018105560A1 (ja) | 2016-12-07 | 2018-06-14 | 国立大学法人大阪大学 | Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬 |
| EP3580212A4 (en) | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| CN109796532B (zh) * | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| MA51428A (fr) | 2017-12-22 | 2020-11-04 | Bluebird Bio Inc | Récepteur d'antigène chimérique multivalent |
| KR102804816B1 (ko) | 2018-03-09 | 2025-05-09 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd73 항체 및 이의 용도 |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2021061708A1 (en) | 2019-09-23 | 2021-04-01 | The Trustees Of The Univeristy Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
| EP4228601A4 (en) | 2020-10-13 | 2025-08-06 | Univ Pennsylvania | IN VIVO TARGETING OF FIBROSIS BY TARGETING ANTI-CD5 IN MRNA-LNP FAP-CAR-T |
-
2020
- 2020-09-23 AU AU2020353000A patent/AU2020353000A1/en active Pending
- 2020-09-23 EP EP20870352.0A patent/EP4034554A4/en active Pending
- 2020-09-23 JP JP2022518209A patent/JP7621344B2/ja active Active
- 2020-09-23 CN CN202080079493.6A patent/CN114746438A/zh active Pending
- 2020-09-23 CA CA3151550A patent/CA3151550A1/en active Pending
- 2020-09-23 WO PCT/US2020/052227 patent/WO2021061778A1/en not_active Ceased
- 2020-09-23 US US17/029,702 patent/US12116418B2/en active Active
- 2020-09-23 KR KR1020227012360A patent/KR20220066312A/ko active Pending
- 2020-09-23 MX MX2022003466A patent/MX2022003466A/es unknown
- 2020-09-23 BR BR112022005423A patent/BR112022005423A2/pt unknown
-
2022
- 2022-03-14 IL IL291342A patent/IL291342A/en unknown
- 2022-03-25 ZA ZA2022/03511A patent/ZA202203511B/en unknown
-
2024
- 2024-07-18 US US18/776,496 patent/US20250011472A1/en active Pending